Lineage Cell Therapeutics (LCTX) Non-Current Deferred Tax Liability (2013 - 2026)

Lineage Cell Therapeutics' Non-Current Deferred Tax Liability history runs 14 years deep, the most recent figure standing at $22000.0 for Q1 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability fell 91.94% year-over-year to $22000.0 in Q1 2026; TTM through Mar 2026 was $22000.0, a 91.94% decrease from a year earlier, with the FY2025 full-year figure at $22000.0, down 91.94% from the prior year.
• Non-Current Deferred Tax Liability held at $22000.0 in Q1 2026 per LCTX's latest filing, from $22000.0 in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $2.1 million in Q1 2022 and bottomed at $22000.0 in Q4 2025.
• The 5-year median for Non-Current Deferred Tax Liability is $273000.0 (2023), against an average of $667705.9.
• Across the five-year window, Non-Current Deferred Tax Liability jumped 132.21% in 2022 and plunged 91.94% in 2025, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $2.1 million in 2022, then plunged by 86.85% to $273000.0 in 2023, then changed by 0.0% to $273000.0 in 2024, then plunged by 91.94% to $22000.0 in 2025, then changed by 0.0% to $22000.0 in 2026.
• Per Business Quant, the three latest LCTX Non-Current Deferred Tax Liability figures stand at $22000.0 (Q1 2026), $22000.0 (Q4 2025), and $273000.0 (Q3 2025).